Royal Bank of Canada’s Capricor Therapeutics CAPR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $112K | Sell |
3,695
-1,345
| -27% | -$35.8K | ﹤0.01% | 5060 |
|
|
2025
Q4 | $146K | Buy |
5,040
+557
| +12% | +$7.27K | ﹤0.01% | 4976 |
|
|
2025
Q3 | $32K | Buy |
4,483
+529
| +13% | +$3.9K | ﹤0.01% | 6012 |
|
|
2025
Q2 | $39K | Sell |
3,954
-1,415
| -26% | -$14.9K | ﹤0.01% | 6016 |
|
|
2025
Q1 | $51K | Buy |
5,369
+240
| +5% | +$3.33K | ﹤0.01% | 5564 |
|
|
2024
Q4 | $71K | Sell |
5,129
-2,074
| -29% | -$36.3K | ﹤0.01% | 5510 |
|
|
2024
Q3 | $110K | Buy |
7,203
+846
| +13% | +$4.18K | ﹤0.01% | 5273 |
|
|
2024
Q2 | $30K | Buy |
6,357
+4,957
| +354% | +$27.6K | ﹤0.01% | 5884 |
|
|
2024
Q1 | $10K | Sell |
1,400
-8,578
| -86% | -$41.5K | ﹤0.01% | 6189 |
|
|
2023
Q4 | $49K | Buy |
9,978
+8,578
| +613% | +$27.9K | ﹤0.01% | 5998 |
|
|
2023
Q3 | $5K | Sell |
1,400
-228
| -14% | -$1.28K | ﹤0.01% | 6601 |
|
|
2023
Q2 | $8K | Buy |
1,628
+228
| +16% | +$1K | ﹤0.01% | 6529 |
|
|
2023
Q1 | $6K | Buy |
+1,400
| New | +$6.03K | ﹤0.01% | 6497 |
|
|
2022
Q4 | – | Sell |
-4
| Closed | – | – | 7252 |
|
|
2022
Q3 | $0 | Sell |
4
-496
| -99% | -$2.54K | ﹤0.01% | 7466 |
|
|
2022
Q2 | $2K | Hold |
500
| – | – | ﹤0.01% | 6924 |
|
|
2022
Q1 | $2K | Buy |
+500
| New | +$1.97K | ﹤0.01% | 7463 |
|
|
2021
Q3 | – | Sell |
-1,387
| Closed | -$7K | – | 7640 |
|
|
2021
Q2 | $7K | Sell |
1,387
-22
| -2% | -$93 | ﹤0.01% | 6968 |
|
|
2021
Q1 | $6K | Sell |
1,409
-15
| -1% | -$86 | ﹤0.01% | 6982 |
|
|
2020
Q4 | $5K | Buy |
1,424
+49
| +4% | +$212 | ﹤0.01% | 6623 |
|
|
2020
Q3 | $7K | Sell |
1,375
-1,650
| -55% | -$9.62K | ﹤0.01% | 6036 |
|
|
2020
Q2 | $14K | Buy |
3,025
+1,375
| +83% | +$5.99K | ﹤0.01% | 5712 |
|
|
2020
Q1 | $2K | Buy |
1,650
+1,013
| +159% | +$1.41K | ﹤0.01% | 6274 |
|
|
2019
Q4 | $1K | Buy |
637
+1
| +0.2% | +$2 | ﹤0.01% | 6631 |
|
|
2019
Q3 | $3K | Hold |
636
| – | – | ﹤0.01% | 6179 |
|
|
2019
Q2 | $2K | Buy |
636
+633
| +21,100% | +$2.65K | ﹤0.01% | 6557 |
|
|
2019
Q1 | $0 | Hold |
3
| – | – | ﹤0.01% | 6817 |
|
|
2018
Q4 | $0 | Sell |
3
-23
| -88% | -$183 | ﹤0.01% | 6768 |
|
|
2018
Q3 | $0 | Buy |
26
+3
| +13% | +$36 | ﹤0.01% | 6725 |
|
|
2018
Q2 | $0 | Hold |
23
| – | – | ﹤0.01% | 6523 |
|
|
2018
Q1 | $0 | Hold |
23
| – | – | ﹤0.01% | 6363 |
|
|
2017
Q4 | $0 | Hold |
23
| – | – | ﹤0.01% | 6549 |
|
|
2017
Q3 | $1K | Hold |
23
| – | – | ﹤0.01% | 6610 |
|
|
2017
Q2 | $0 | Buy |
+23
| New | +$421 | ﹤0.01% | 6569 |
|
Other funds holding CAPR
SCM
TCM
VCM
RCM
JHC
Royal Bank of Canada's CAPR Position: Q1 2026 in Review
Royal Bank of Canada reduced its Capricor Therapeutics (CAPR) stake by 27% in Q1 2026, selling an estimated $35.8K and leaving 3,695 shares worth $112K. The position accounts for ﹤0.01% of the portfolio, ranked #5060.
Royal Bank of Canada first reported a position in CAPR in Q2 2017 and has held it in 33 quarters since. The position peaked at $146K in Q4 2025. 177 funds tracked by Wall St. Rank hold CAPR as of Q1 2026.
- Royal Bank of Canada held 3,695 shares of Capricor Therapeutics worth $112K as of Q1 2026.
- Royal Bank of Canada sold 1,345 Capricor Therapeutics shares in Q1 2026, an estimated $35.8K.
- Capricor Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #5060 holding.
- Royal Bank of Canada first reported a position in Capricor Therapeutics in Q2 2017 and has held it in 33 quarters since.
- Royal Bank of Canada's Capricor Therapeutics position peaked at $146K in Q4 2025.
- 177 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q1 2026.
Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.